Figure 2 | British Journal of Cancer

Figure 2

From: Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

Figure 2

Eribulin reverses EMT and induces MET in MX-1 breast cancer xenografts in vivo. (A) Schematic representation of treatment scheme. (B) Representative IHC images of E-cadherin (upper), N-cadherin (middle), and ZEB1 (lower) in tumour specimens from animals treated with 0.3, 1, and 3 mg kg−1 eribulin. Images taken at × 100 magnification. (C) Quantification of IHC staining of the markers shown in (B). Data for individual tumours are presented as points, with means±s.e.m. of the group shown by lines (n=10). ***P<0.001, ****P<0.0001 vs control group (Dunnett-type multiple comparison test).

Back to article page